ACE and coronary artery disorder: Some participants had the co-morbidities of CAD (67.6%) and hypertension (73.3%), and used the non-steroidal anti-inflammatory drugs (NSAIDs, 61.0%) and angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs, 55.2%).